157 related articles for article (PubMed ID: 21788991)
1. Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.
Ananthakrishnan AN; Hur C; Juillerat P; Korzenik JR
Am J Gastroenterol; 2011 Nov; 106(11):2009-17. PubMed ID: 21788991
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis.
Saito S; Shimizu U; Nan Z; Mandai N; Yokoyama J; Terajima K; Akazawa K
J Crohns Colitis; 2013 Mar; 7(2):167-74. PubMed ID: 22626508
[TBL] [Abstract][Full Text] [Related]
3. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease.
Doherty GA; Miksad RA; Cheifetz AS; Moss AC
Inflamm Bowel Dis; 2012 Sep; 18(9):1608-16. PubMed ID: 21905173
[TBL] [Abstract][Full Text] [Related]
4. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
Tsai HH; Punekar YS; Morris J; Fortun P
Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
[TBL] [Abstract][Full Text] [Related]
5. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
Lindsay J; Punekar YS; Morris J; Chung-Faye G
Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
[TBL] [Abstract][Full Text] [Related]
6. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab.
Mantzaris GJ; Viazis N; Petraki K; Papamichael K; Theodoropoulos I; Roussos A; Karakoidas C; Koilakou S; Raptis N; Smyrnidis A; Agalos G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1042-8. PubMed ID: 20139856
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
Tang DH; Armstrong EP; Lee JK
Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
[TBL] [Abstract][Full Text] [Related]
8. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.
Ananthakrishnan AN; Korzenik JR; Hur C
Inflamm Bowel Dis; 2013 Jan; 19(1):37-44. PubMed ID: 22416019
[TBL] [Abstract][Full Text] [Related]
9. Azathioprine or ileocolic resection for steroid-dependent terminal ileal Crohn's disease? A Markov analysis.
Kennedy ED; Urbach DR; Krahn MD; Steinhart AH; Cohen Z; McLeod RS
Dis Colon Rectum; 2004 Dec; 47(12):2120-30. PubMed ID: 15657664
[TBL] [Abstract][Full Text] [Related]
10. Risks and benefits of infliximab for the treatment of Crohn's disease.
Siegel CA; Hur C; Korzenik JR; Gazelle GS; Sands BE
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1017-24; quiz 976. PubMed ID: 16843733
[TBL] [Abstract][Full Text] [Related]
11. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.
Kaplan GG; Hur C; Korzenik J; Sands BE
Aliment Pharmacol Ther; 2007 Dec; 26(11-12):1509-20. PubMed ID: 17931345
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.
Dubinsky MC; Reyes E; Ofman J; Chiou CF; Wade S; Sandborn WJ
Am J Gastroenterol; 2005 Oct; 100(10):2239-47. PubMed ID: 16181376
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.
Marchetti M; Liberato NL; Di Sabatino A; Corazza GR
Eur J Health Econ; 2013 Dec; 14(6):853-61. PubMed ID: 22975794
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
15. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab.
Velayos FS; Kahn JG; Sandborn WJ; Feagan BG
Clin Gastroenterol Hepatol; 2013 Jun; 11(6):654-66. PubMed ID: 23357488
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD.
Miller SM; Goldstein JL; Gerson LB
Am J Gastroenterol; 2011 Aug; 106(8):1439-45. PubMed ID: 21448144
[TBL] [Abstract][Full Text] [Related]
17. Resource use in patients with Crohn's disease treated with infliximab.
Saro C; da la Coba C; Casado MA; Morales JM; Otero B
Aliment Pharmacol Ther; 2007 Nov; 26(10):1313-23. PubMed ID: 17850419
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
[TBL] [Abstract][Full Text] [Related]
19. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
Wynands J; Belbouab R; Candon S; Talbotec C; Mougenot JF; Chatenoud L; Schmitz J; Cézard JP; Goulet O; Hugot JP; Ruemmele FM
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):293-8. PubMed ID: 18376247
[TBL] [Abstract][Full Text] [Related]
20. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?
Canedo J; Lee SH; Pinto R; Murad-Regadas S; Rosen L; Wexner SD
Colorectal Dis; 2011 Nov; 13(11):1294-8. PubMed ID: 20969715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
